Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease.

Muhammad Waqas SadiqHongtao YuMagnus ÅstrandIan C ScottAdam WilliamsLisa HewittNicholas WhiteHelen KillickMonica GavalaE Suzanne CohenFred ReidChris KellHitesh PandyaEulalia Jimenez

Published in: British journal of clinical pharmacology (2024)

The PK/TE model reliably quantified the relationship between PK and systemic TE of tozorakimab, with potential utility for predicting clinical dose-response relationships and supporting clinical dose selection.

Keyphrases

risk assessment
climate change
human health